Millie
your market intelligence analyst
Search Results
Edit Save
125,718 results
The selections or defaults defined for this collection may have been too restrictive for this search query. You can refine your results for this search.
Retail Times (UK) 11/15/2019 07:27
It has been well documented that traditional sectors like retail and banking are under pressure in a changing world and where customer expectations are constantly evolving. For our high street there is a growing list of pressures, especially when it comes to consumer demand for convenience, range, speed of delivery and competitive pricing, and while this is a wake up call for UK brands, growth is still possible to find as UK retail continues to evolve.r.
Point (Gambia) 11/15/2019 07:23
Brikama, Foni and Farafenni have all sealed wins in the ongoing Africell-sponsored super nawettan after winning their respective group games played on Wednesday. The Sateyba boys battered whipping boys Serrekunda Central 3-1 at the Father Gough Sports Complex in Manjai Kunda to grip 9 points after four group matches. The Foni boys thrashed drubbing Jarra and Kiang United (JAKU) side 3-0 at the Serrekunda West Mini Stadium to clinch 6 points after three group games. They need a win...
FoneArena (India) 11/15/2019 07:22
Realme is all set to launch its flagship smartphone, realme X2 Pro in India on November 20 along with realme 5s. Ahead of the launch, the company has announced Blind Order sale of realme X2 Pro that will let realme fans and customers pre-order realme X2 Pro on November 18th, 2019 by simply registering themselves on realme.com. How to place realme X2 Pro Blind Order. Visit realme.com on 18th November. The exact timing is not announced yet, but it is likely to be 12 Noon. Login using your realme ID. Follow the steps on the blind order page and pay ₹1000 as a deposit which in-turn ensures their 100% chance to buy the all-new realme X2 Pro (Only for first 855 customers). Pay balance due from 20th to 21st November. The product will be dispatched fro.
GlobeNewswire 11/15/2019 07:18
Basel, 15 November 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.

Energy

Business Issues

Companies - Public

Companies - Venture Funded

Chemicals - Agricultural

Chemicals - Industrial

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Political Entities

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications